Roflumilast cream (0.3%) is a novel, nonsteroidal cream, that has demonstrated safety and efficacy for use in plaque psoriasis, seborrheic dermatitis, and mild-to-moderate atopic dermatitis by inhibiting phoshodiesterase 4 (PDE4).6,7 PDE4 inhibitors have been shown to reduce hyperproliferation of keratinocytes in human skin,8 and, therefore, could potentially aid in the treatment of follicular keratotic disorders. This evidence concerns the gene PDE4A and psoriasis vulgaris.